Distinctive features of polycythaemia vera in New Zealand Polynesians

N Z Med J. 2018 Sep 21;131(1482):38-45.

Abstract

Aim: The aim of this study was to examine a potential ethnic disparity in the phenotype of polycythaemia vera (PV) between New Zealand European and Polynesian patients.

Method: A retrospective review of medical records was conducted at Middlemore Hospital to identify adult patients with PV diagnosed between 1987 and 2007. Data extracted included diagnostic criteria, ethnicity, age, complications and survival.

Results: Eighty-eight adult patients with PV were identified during 1987-2007, 49 (55.7%) were Europeans and 36 (40.9%) Polynesians. The most striking finding was that Polynesian patients presented almost 14 years younger than Europeans (mean age of 54 years versus [vs] 68, respectively; P<.001). The white cell and platelet counts were higher in Polynesians compared with Europeans (mean white cell count of 22x109/L vs 13x109/L; mean platelet count of 648x109/L vs 512x109/L, respectively; P<.05 for both). The rate of JAK2 V617F mutation in Polynesians was 96%, equivalent to other large cohorts of European patients. The rates of long-term complications were comparable between Polynesians and Europeans, but the predicted impact on life expectancy was more severe for Polynesians.

Conclusion: New Zealand Polynesian patients present with a distinctive PV phenotype. Their younger age at presentation suggests a different risk factor profile or a higher genetic susceptibility. We hope our observations initiate larger epidemiological and genetic studies to help elucidate the cause.

MeSH terms

  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Health Status Disparities
  • Hemoglobins / analysis
  • Humans
  • Janus Kinase 2 / genetics
  • Leukemia, Myeloid, Acute / epidemiology
  • Leukocyte Count
  • Life Expectancy
  • Male
  • Middle Aged
  • Mutation
  • Native Hawaiian or Other Pacific Islander*
  • New Zealand / epidemiology
  • Platelet Count
  • Polycythemia Vera / ethnology*
  • Polycythemia Vera / genetics
  • Polycythemia Vera / mortality
  • Primary Myelofibrosis / epidemiology
  • Retrospective Studies
  • Splenomegaly

Substances

  • Hemoglobins
  • JAK2 protein, human
  • Janus Kinase 2